Search the Newsreel

Kestra Medical Technologies (KMTS) insider schedules 2,380-share stock sale after award vesting

Kestra Medical Technologies (KMTS) has reported that an insider plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026, with an estimated aggregate market value of $56,551.44. These shares were obtained from performance share unit awards that vested on …

Kestra Medical (KMTS) insider files to sell 7,590 common shares

An insider at Kestra Medical Technologies, Ltd. (KMTS), Traci Umberger, has filed to sell 7,590 shares of common stock under Rule 144, valued at approximately $181,061.84. The planned sale will be executed through Merrill Lynch on or after August 3, 2026, and is related …

Kestra Medical Technologies (KMTS) insider plans 5,391-share stock sale after awards vest

Kestra Medical Technologies (KMTS) has reported a planned sale of 5,391 shares of common stock with an indicated value of $128,312.27, scheduled for August 3, 2026, through Merrill Lynch on NASDAQ. These shares are related to performance share unit awards that vested on July …

Kestra Medical Technologies CEO sells $692k in shares

Kestra Medical Technologies, Ltd.'s President and CEO, Brian Daniel Webster, sold 51,900 common shares of KMTS on August 4, 2026, across three transactions. These "sell to cover" sales were nondiscretionary and executed to satisfy tax withholding obligations related to the vesting of restricted stock …

Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 13,015 Shares of Stock

Kestra Medical Technologies (KMTS) has disclosed a planned sale of 13,015 shares of common stock through Merrill Lynch on or about July 31, 2026, stemming from vested performance share unit awards. The aggregate market value of this planned sale is approximately $311,118.83. Additionally, an …

Kestra Medical (KMTS) executive files Rule 144 notice for potential stock sale

Vaseem Mahboob, an executive at Kestra Medical Technologies, Ltd. (KMTS), has filed a Rule 144 notice to sell common stock through Merrill Lynch on or after July 31, 2026. These shares were acquired via the vesting of performance share unit awards on July 17, …

Kestra Medical Technologies (KMTS) insider files to sell 8,759 shares under Rule 144

Kestra Medical Technologies insider Timothy Moran has filed a notice to sell up to 8,759 shares of common stock under Rule 144, with an aggregate market value of $198,000.29 as of July 31, 2026. These shares are from vested performance share unit awards. The …

Kestra Medical Technologies (KMTS) insider plans $196K Rule 144 stock sale

An insider at Kestra Medical Technologies (KMTS), Alfred J Ford, plans to sell 8,681 shares of common stock under Rule 144, valued at approximately $196,284.58. The sale, expected on July 31, 2026, involves shares from performance share unit awards that vested on July 17, …

Kestra Medical Technologies (KMTS) plans sale of 7,857 shares from equity award

Kestra Medical Technologies (KMTS) has disclosed a planned sale of 7,857 common shares through Merrill Lynch on July 30, 2026. These shares originated from a performance stock issuance on July 17, 2026, under an equity compensation plan. The filing also notes recent sales over …

Kestra Medical Technologies (KMTS) plans sale of 5,887 vested shares

Kestra Medical Technologies (KMTS) has filed notice to sell 5,887 shares of common stock through Merrill Lynch on or about July 30, 2026. These shares, with an aggregate market value of $133,892.22, stem from the vesting of performance share unit awards on July 17, …

Kestra Medical Technologies (KMTS) holder to resell 5,936 vested shares

A security holder of Kestra Medical Technologies (KMTS) plans to resell 5,936 shares of common stock through Merrill Lynch on or after July 30, 2026, on NASDAQ. These shares, valued at approximately $135,120.73, originated from the vesting of performance share unit awards on July …

Kestra Medical Technologies (NASDAQ: KMTS) details 2026 proxy proposals

Kestra Medical Technologies (KMTS) has released details for its 2026 Annual General Meeting, scheduled for September 9, 2026. Shareholders will vote on the re-election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The proxy …

KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing (Jul 28, 2026)

This article reports on an SEC filing (Form ARS) made by KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on July 28, 2026, at 4:30 PM, concerning its annual report. The filing is categorized with low impact and neutral sentiment. The article also provides a brief overview …

Kestra Medical Technologies Ltd (KMTS) Cash Flow

This article presents the detailed quarterly and annual cash flow statements for Kestra Medical Technologies Ltd (KMTS), covering operating, investing, and financing cash flows. It includes financial figures for multiple recent fiscal quarters and offers explanations for key cash flow metrics like operating cash …

Kestra Medical Technologies (KMTS) Secures $200 Million Debt Facility Without New Equity

Kestra Medical Technologies (KMTS) has secured a $200 million non-dilutive five-year term loan facility, refinancing existing debt and maintaining a strong cash position. This financing provides the company with flexibility to manage operations and pursue growth opportunities without issuing new equity, despite its ongoing …

KMTS|Kestra Medical Technologies Ltd|Price:21.060|Chg%:-0.510

Kestra Medical Technologies Ltd (KMTS) is a commercial-stage medical device and digital healthcare company focusing on cardiovascular disease. The company's core product is the Cardiac Recovery System platform, which includes the ASSURE WCD for sudden cardiac arrest risk. KMTS has a market cap of …

Kestra Medical Technologies Ltd

This article provides an overview of Kestra Medical Technologies Ltd (KMTS), including its current stock price and market capitalization. It notes that revenue breakdown by business segments and region has not been disclosed by the company. The page appears to be a financial data …

Kestra Medical Technologies (NASDAQ:KMTS) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on Kestra Medical Technologies (NASDAQ:KMTS) with a "market perform" rating, while other analysts have a mixed view, with an overall "Hold" consensus and an average price target of $27.83. The stock recently dropped 4.8% to $23.24 after the company missed earnings …

Goodwin Guides IP For Pharmakon On Up To $200 Million Financing For Kestra Medical Technologies

Goodwin Procter LLP advised Pharmakon Advisors, LP, on the intellectual property aspects of a five-year term loan facility for Kestra Medical Technologies. This financing provides Kestra Medical with up to $200 million in non-dilutive funds, structured in multiple tranches. The aim is to bolster …

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Recommendation of "Hold" from Brokerages

Kestra Medical Technologies (NASDAQ:KMTS) has received a consensus "Hold" rating from five brokerages, with an average 12-month price target of $27.83. The company recently missed earnings expectations, reporting ($0.67) EPS against a projected ($0.59), and shares were up 1.8% to $24.42 despite an insider …

Kestra Medical Technologies Insider Sold Shares Worth $336,609, According to a Recent SEC Filing

An insider at Kestra Medical Technologies recently sold shares totaling $336,609, as disclosed in a new SEC filing. The details of this transaction will provide insights into insider sentiment regarding the company's stock. Investors often monitor such filings for signals about a company's prospects.

Kestra Medical Technologies CEO Webster sells $336,609 in stock

Brian Daniel Webster, CEO of Kestra Medical Technologies (NASDAQ:KMTS), sold 15,000 common shares totaling $336,609 on July 15, 2026, under a Rule 10b5-1 trading plan. This sale occurred following his acquisition of 176,470 shares from vested performance-based Restricted Stock Units. Despite recent strong revenue …

Kestra Medical (KMTS) counsel earns 58,832-share stock award

Kestra Medical Technologies, Ltd. reported that its General Counsel, Traci S. Umberger, acquired 58,832 Common Shares on July 15, 2026, through the vesting of performance-based Restricted Stock Units (PSUs). These PSUs were granted on July 17, 2025, and vested at a 100% rate, resulting …

Kestra Medical Technologies (KMTS) awards 39,113 shares to its CBO

Kestra Medical Technologies' Chief Business Officer, Timothy P. Moran, was awarded 39,113 common shares from performance-based restricted stock units (PSUs) that vested on July 15, 2026. These shares were granted on July 17, 2025, and vested after specific performance goals were achieved, increasing Moran's …

Press Release: Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies has announced it secured up to $200 million in non-dilutive financing from Sixth Street. This substantial funding is intended to support the company's continued growth, product development, and market expansion. The financing will enable Kestra to further innovate in its field …

Kestra Medical Technologies, Ltd. Stock 12‑Month Price Target Raised to $28.43, Implies 18% Upside

Analysts have raised the average 12-month price target for Kestra Medical Technologies, Ltd. (KMTS) stock from $27.71 to $28.43, suggesting an 18% potential upside from its July 14 closing price. The consensus rating from 7 analysts remains a "Buy," with 6 buys and 1 …

Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land

Kestra Medical Technologies (KMTS) shares are under scrutiny after recent earnings, 2027 revenue guidance, and a new term loan facility. Despite a significant 1-year share price increase of 60.4%, the analysis suggests the company might be 31% overvalued, with a fair value estimate of …

Kestra Medical (NASDAQ: KMTS) investor Brian Webster plans 15,000-share sale

Brian Webster, an investor in Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), has filed a notice for the potential sale of 15,000 common shares valued at $336,609.41. These shares were initially acquired on January 1, 2026, through a restricted share issuance as part of the …

Kestra Medical (NASDAQ: KMTS) targets $24B wearable defibrillator market

Kestra Medical Technologies (KMTS) is a commercial-stage company focused on cardiac recovery with its ASSURE wearable cardioverter defibrillator (WCD) system. The company aims to capture a significant portion of the estimated $24 billion global WCD market, highlighting its patient-centered design and strong clinical evidence. …

KESTRA MEDICAL TECHNOLOGIES, LTD. Q4 2026 Earnings Call Summary

KESTRA MEDICAL TECHNOLOGIES ($KMTS) Releases Q4 2026 Earnings

Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares

Kestra Medical Technologies (KMTS) Revenue Growth Versus Ongoing EPS Losses Tests Bullish Narratives

Kestra Medical Earnings: Revenue Doubles as Cardiac Device Prescriptions Soar 72%